Asymmetric Healthcare Portfolio: up 1.47% in June 2025! 📈

Asymmetric Healthcare Portfolio delivered a 1.47% gain in June and a total 3.51% increase in value since the portfolio launch back in the mid of May 2025. 📈

Portfolio page is updated with the details. 🗂️
I have my skin in the game, this portfolio is not a model portfolio. Paid subscribers are able to see proof of transactions.

Below is a detailed update about each equity in the portfolio. 📝

Genmab (GMAB): pipeline power meets market turbulence! 🧬

GMAB took us on a mini roller coaster in June, sliding from around $22 to closer to $20 by month's end! 😬 This is not a Genmab-specific meltdown! The ENTIRE biotech sector has been getting hammered lately, so GMAB are just caught in the crossfire!

The game-changing pipeline news! 🚀🎯

Genmab just published some absolutely STELLAR Phase 2 data for Epcoritamab (their lymphoma-fighting antibody superhero)! 🦸‍♂️💪

The result is strong response rates in patients with relapsed/refractory diffuse large B-cell lymphoma! 📊✨ This is the kind of data that makes investors happy.

Epcoritamab is one of their CROWN JEWELS and every positive data point is fuel to their long-term story! 🚀⛽

Partnership power-up: AbbVie alliance expands! 🤝💰

Genmab just SUPERCHARGED their partnership with AbbVie, diving deeper into antibody therapy collaboration! 🔬🤖 This means potential milestone payments that could keep the cash register ringing for YEARS! 💸🎰

I'm absolutely LOVING these partnerships because they're like having a safety net: shared risk, shared rewards and MORE money for R&D adventures! 🎪💡

Diamond in the rough! 💎🔍

Genmab is a HIGH-QUALITY biotech beast with:

• ✅ killer pipeline (epcoritamab is just the beginning!)

• ✅ fortress balance sheet (that$2B+ cash cushion!)

• ✅ smart partnerships (AbbVie collaboration = WIN!)

• ✅ proven track record

The stock price might continue to be volatile especially while the broader market is having its mood swings! But the long term story is ROCK SOLID! 🪨💪

Patience pays in Biotech! ⏰💰

If you can handle the volatility roller coaster and have the patience, GMAB stays a PREMIUM pick in the biotech Code Playground! 🎪🏆 The fundamentals haven't changed. They are still innovating, still cash-rich and still delivering results where it counts!

---

Merck (MRK): the pharma giant fighting back! 💊🥊

Let's address the BIG worry first: everyone's concerned about Keytruda product's patent expiring in 2028! This cancer-fighting SUPERSTAR has been Merck's cash cow for years and investors are basically asking "What happens when the golden goose stops laying eggs?" 🥚💰

Pipeline EXPLOSION: 20 potential blockbusters! 🚀💥

Merck has got about 20 NEW potential blockbuster drugs in development with a combined sales potential of $50 BILLION!* 🤯💰

That is impressive.

The June standouts:

• MK-1022 for lung cancer (could hit$5B+ in peak sales!) 🫁💊

• MK-0616 - potentially the FIRST oral PCSK9 inhibitor for cholesterol (another$5B+ monster!) 💊❤️

These are potential GAME CHANGERS! 🎮🔥

New launches already CRUSHING IT! 📈⚡

Winrevair is absolutely FLYING! 🛩️ This pulmonary arterial hypertension treatment just scored FDA priority review after STELLAR Phase 3 results! Sales are ramping up fast and Merck thinks it's at least a $3 billion drug.

Capvaxive (their vaccine) is also off to a rocket start and could easily become another $2 billion cash machine! 💉🚀

Stock Price: BARGAIN ALERT! 🛒💎

Here's where it gets JUICY for value hunters! 🕵️‍♂️ MRK is trading around$80, which is BELOW its usual price-to-sales ratio! Some analysts are saying there's 40% upside just from returning to historical averages! 📊📈

July 29 Earnings! 📅🎪

Q2 earnings on July 29 will be the MOMENT OF TRUTH, we'll see if these new drugs are living up to the hype and whether Merck can keep beating estimates like they've been doing! 🎯📊

My take

June was all about steady, strategic progress for Merck! 💪 Sure, they're facing the Keytruda cliff, but management is playing 4D chess to prepare for the post-Keytruda era! ♟️🧠

What I LOVE about MRK: ✅

• Massive pipeline (20 potential blockbusters!)

• New launches already winning (Winrevair, Capvaxive!)

• Attractive valuation (trading below historical norms!)

• Solid dividend (reliable income stream!)

• Proven management (they know how to execute!)

This isn't a get-rich-quick moonshot, it's a solid, dependable play for patient investors! 🐢💎

The verdict: If you can handle a little uncertainty and believe in Merck's ability to reinvent itself, MRK is still a winner for me.

---